Ozempic and Wegovy have propelled Novo Nordisk to Europe’s second-most valuable company. Now it faces a struggle to keep up. Bloomberg’s Suzi Ring reports.
--------
Subscribe to our YouTube channel: [ Ссылка ]
Subscribe to Bloomberg Originals: [ Ссылка ]
Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
Connect with us on…
YouTube: [ Ссылка ]
Breaking News on YouTube: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
